COLUMBIA, Md., Dec. 19, 2017 /PRNewswire/ — Today’s U.S. Food and Drug Administration (FDA) approval of voretigene neparvovec, to be marketed as LUXTURNA™, will be life-changing for patients with vision loss due to mutations in the RPE65 gene and a watershed moment for the inherited…
